{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:00:51Z","timestamp":1785160851755,"version":"3.55.0"},"reference-count":118,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>\n                    Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune\u2010mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity. The liver and other organ systems can also be affected. The\n                    <jats:italic>HLA<\/jats:italic>\n                    alleles,\n                    <jats:italic>HLA\u2010B*15:02<\/jats:italic>\n                    ,\n                    <jats:italic>HLA\u2010B*15:11<\/jats:italic>\n                    and\n                    <jats:italic>HLA\u2010A*31:01<\/jats:italic>\n                    , are known predisposing factors for these hypersensitivity reactions. Any treatment\u2010na\u00efve patient, regardless of ancestry or indication for treatment, who is about to be prescribed carbamazepine, oxcarbazepine or eslicarbazepine, or has been on these drugs for less than 3\u2009months, should undergo pharmacogenetic testing to identify all clinically relevant\n                    <jats:italic>HLA<\/jats:italic>\n                    alleles to reduce the risk of hypersensitivity reactions. Carbamazepine, oxcarbazepine and eslicarbazepine should be avoided in\n                    <jats:italic>HLA\u2010B*15:02<\/jats:italic>\n                    \u2010positive patients. These drugs should also be avoided in patients positive for\n                    <jats:italic>HLA\u2010A*31:01<\/jats:italic>\n                    or\n                    <jats:italic>HLA\u2010B*15:11<\/jats:italic>\n                    if an alternative is possible. Where it is not possible to use an alternative, treatment should only be commenced after careful consideration of the benefits and risks, with increased monitoring and advising patients on appropriate action to take if a skin rash occurs. Our guideline is compatible with other international pharmacogenetics prescribing guidelines. This guideline is grounded in the latest evidence but cannot account for all individual factors relevant to patient care. Therefore, prescribers must conduct a thorough assessment of each patient's risk\u2013benefit profile, ensuring that therapy is optimised to maximise benefits whilst minimising potential harms.\n                  <\/jats:p>","DOI":"10.1002\/bcp.70559","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:25:49Z","timestamp":1776644749000},"page":"1957-1976","source":"Crossref","is-referenced-by-count":2,"title":["<i>HLA<\/i>\n                    genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI\u2010PGx)"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8396-7855","authenticated-orcid":false,"given":"Lucy","family":"Galloway","sequence":"first","affiliation":[{"name":"NHS South East Genomic Medicine Service St George's University Hospitals NHS Foundation Trust  London UK"},{"name":"Faculty of Life Sciences &amp; Medicine King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-3832","authenticated-orcid":false,"given":"Cinzia","family":"Dello Russo","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"Department of Translational Medicine and Surgery, Section of Pharmacology Universit\u00e0 Cattolica del Sacro Cuore\u2014Fondazione Policlinico Universitario A. Gemelli, IRCCS  Rome Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Bass","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Bramon","sequence":"additional","affiliation":[{"name":"Division of Psychiatry University College London  London UK"},{"name":"North London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cross","sequence":"additional","affiliation":[{"name":"University College London Great Ormond Street Institute of Child Health  London UK"},{"name":"Great Ormond Street Hospital for Children NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Curley","sequence":"additional","affiliation":[{"name":"NHS South West London Integrated Care Board  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Curran","sequence":"additional","affiliation":[{"name":"South London and Maudsley NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Davies","sequence":"additional","affiliation":[{"name":"Cwm Taf Morgannwg University Health Board  Abercynon UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"De Villiers","sequence":"additional","affiliation":[{"name":"The State Hospitals Boards for Scotland  Lanark UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Evans","sequence":"additional","affiliation":[{"name":"Yorkshire Regional Genetics Service  Leeds UK"},{"name":"Gibson Lane Practice  Leeds UK"},{"name":"School of Medicine University of Nottingham  Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Frank","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Groves","sequence":"additional","affiliation":[{"name":"Urgent Care Division Aneurin Bevan University Health Board  Newport UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hayward","sequence":"additional","affiliation":[{"name":"National Genomics Education Programme, NHS England  London UK"},{"name":"NHS North West Genomic Medicine Service  Manchester UK"},{"name":"Shipley Medical Practice Affinity Care  Shipley UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Higham","sequence":"additional","affiliation":[{"name":"Birmingham Community Healthcare NHS Foundation Trust and Birmingham Dental Hospital  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8247-7459","authenticated-orcid":false,"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation North Wales Medical School Bangor University  Bangor UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwe Sin","family":"Kyaw","sequence":"additional","affiliation":[{"name":"Centre for Health Economics and Medicines Evaluation North Wales Medical School Bangor University  Bangor UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G.","family":"Marson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"The Walton Centre NHS Foundation Trust  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailsa","family":"McLellan","sequence":"additional","affiliation":[{"name":"Royal Hospital for Children and Young People  Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Mensah","sequence":"additional","affiliation":[{"name":"Cardiff and Vale University Health Board  Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"O'Neill","sequence":"additional","affiliation":[{"name":"School of Dentistry, Institute of Life Course and Medical Sciences University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Sargison","sequence":"additional","affiliation":[{"name":"Faculty of Science and Engineering Manchester Metropolitan University  Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay M.","family":"Sisodiya","sequence":"additional","affiliation":[{"name":"Department of Epilepsy, UCL Queen Square Institute of Neurology University College London  London UK"},{"name":"National Hospital for Neurology and Neurosurgery and Chalfont Centre for Epilepsy University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Swan","sequence":"additional","affiliation":[{"name":"NHS Ayrshire and Arran  Ayr UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M.","family":"Zakrewska","sequence":"additional","affiliation":[{"name":"Royal National ENT &amp; Eastman Dental Hospitals University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7266","authenticated-orcid":false,"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Institute of Systems Molecular and Integrative Biology University of Liverpool  Liverpool UK"},{"name":"The Wolfson Centre for Personalised Medicine, Centre for Drug Safety Science University of Liverpool  Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_17_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1004"},{"key":"e_1_2_17_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/44.5.1085"},{"key":"e_1_2_17_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"e_1_2_17_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.103"},{"key":"e_1_2_17_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41431\u2010024\u201001572\u20104"},{"key":"e_1_2_17_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2020.10.018"},{"key":"e_1_2_17_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.07.004"},{"key":"e_1_2_17_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268\u2010017\u20100197\u20105"},{"key":"e_1_2_17_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/00207454.2021.1925667"},{"key":"e_1_2_17_11_1","unstructured":"ClinPGx.Gene\u2010specific information tables for HLA\u2010A and HLA\u2010B.https:\/\/www.clinpgx.org\/page\/hlabRefMaterials. Accessed 23rd October 2025."},{"key":"e_1_2_17_12_1","unstructured":"Gonzalez\u2010Galarza FF McCabe A Santos EJ et alAllele frequency net database.https:\/\/www.allelefrequencies.net\/hla.asp. Updated 2020. Accessed 24th November 2025."},{"key":"e_1_2_17_13_1","unstructured":"Novartis Pharmaceuticals UK Ltd.Tegretol 400mg tablets SmPC.https:\/\/www.medicines.org.uk\/emc\/product\/7846\/smpc. Updated 2025. Accessed 20th October 2025."},{"key":"e_1_2_17_14_1","unstructured":"Novartis Pharmaceuticals UK Ltd.Trileptal 300mg film\u2010coated tablets SmPC.https:\/\/www.medicines.org.uk\/emc\/product\/7851\/smpc. Updated 2025. Accessed 20th October 2025."},{"key":"e_1_2_17_15_1","unstructured":"Bial Pharma UK Ltd.Zebinix 800mg tablets SmPC.https:\/\/www.medicines.org.uk\/emc\/product\/7872\/smpc. Updated 2023. Accessed 20th October 2025."},{"key":"e_1_2_17_16_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Valproate\u2014reproductive risks.https:\/\/www.gov.uk\/guidance\/valproate-reproductive-risks. Updated 2025. Accessed 11th August 2025."},{"key":"e_1_2_17_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_2_17_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2007.01022.x"},{"key":"e_1_2_17_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528\u20101167.2010.02533.x"},{"key":"e_1_2_17_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533\u20102500.2011.00479.x"},{"key":"e_1_2_17_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378\u20106323.57718"},{"key":"e_1_2_17_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.189"},{"key":"e_1_2_17_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2014.09.022"},{"key":"e_1_2_17_24_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102023\u20100054"},{"key":"e_1_2_17_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11596\u2010014\u20101247\u20107"},{"key":"e_1_2_17_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102013\u2010304767"},{"key":"e_1_2_17_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500356"},{"key":"e_1_2_17_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.6.813"},{"key":"e_1_2_17_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617"},{"key":"e_1_2_17_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009717"},{"key":"e_1_2_17_31_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102017\u20100189"},{"key":"e_1_2_17_32_1","doi-asserted-by":"publisher","DOI":"10.18433\/J38G7X"},{"key":"e_1_2_17_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613499791"},{"key":"e_1_2_17_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013297"},{"key":"e_1_2_17_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq537"},{"key":"e_1_2_17_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.09.282"},{"key":"e_1_2_17_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2013.40"},{"key":"e_1_2_17_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1493"},{"key":"e_1_2_17_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.55"},{"key":"e_1_2_17_40_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017\u20101361"},{"key":"e_1_2_17_41_1","doi-asserted-by":"publisher","DOI":"10.18433\/J36S7D"},{"key":"e_1_2_17_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.0278"},{"key":"e_1_2_17_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12937"},{"key":"e_1_2_17_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13867"},{"key":"e_1_2_17_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13291"},{"key":"e_1_2_17_46_1","unstructured":"British Society for Genetic Medicine.Direct\u2010to\u2010consumer genomic testing. Position statement 2025.https:\/\/bsgm.org.uk\/media\/12844\/direct-to-consumer-genomic-testing-joint-position-statement-2025.pdf"},{"key":"e_1_2_17_47_1","unstructured":"National Institute for Health and Care Excellence.Epilepsies in children young people and adults. NICE guideline NG217.https:\/\/www.nice.org.uk\/guidance\/ng217. Updated 2025. Accessed 11th August 2025."},{"key":"e_1_2_17_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2025.02.016"},{"key":"e_1_2_17_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5318"},{"key":"e_1_2_17_50_1","unstructured":"National Institute for Health and Care Excellence.Bipolar disorder: assessment and management. NICE clinical guideline CG185.https:\/\/www.nice.org.uk\/guidance\/cg185. Updated 2023. Accessed 11th August 2025."},{"key":"e_1_2_17_51_1","unstructured":"National Institute for Health and Care Excellence.Neuropathic pain in adults: pharmacological management in non\u2010specialist setting. NICE clinical guideline CG173.https:\/\/www.nice.org.uk\/guidance\/cg173. Updated 2020. Accessed 11th August 2025."},{"key":"e_1_2_17_52_1","unstructured":"Royal College of Surgeons of England.Guidelines for the management of trigeminal neuralgia 2021.https:\/\/www.rcseng.ac.uk\/dental-faculties\/fds\/publications-guidelines\/clinical-guidelines\/. Updated 2021. Accessed 11th August 2025."},{"key":"e_1_2_17_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(25)00068\u20107"},{"key":"e_1_2_17_54_1","unstructured":"Department of Health and Social Care.Clinical guidelines for alcohol treatment.https:\/\/www.gov.uk\/guidance\/clinical-guidelines-for-alcohol-treatment\/10-pharmacological-interventions. Updated 2025. Accessed 12th January 2026."},{"key":"e_1_2_17_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27260"},{"key":"e_1_2_17_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2024.05.004"},{"key":"e_1_2_17_57_1","unstructured":"Desitin Pharma Ltd.Enodama 250mg tablets SmPC.https:\/\/www.medicines.org.uk\/emc\/product\/14779\/smpc. Updated 2025. Accessed 10th March 2026."},{"key":"e_1_2_17_58_1","unstructured":"NHS.Side effects of carbamazepine.https:\/\/www.nhs.uk\/medicines\/carbamazepine\/side-effects-of-carbamazepine\/. Updated 2022. Accessed 22nd January 2026."},{"key":"e_1_2_17_59_1","unstructured":"Royal College of Psychiatrists.The role of genetic testing in mental health settings. College report CR237.https:\/\/www.rcpsych.ac.uk\/improving\u2010care\/campaigning\u2010for\u2010better\u2010mental\u2010health\u2010policy\/college\u2010reports\/2023\u2010college\u2010reports\/the\u2010role\u2010of\u2010genetic\u2010testing\u2010in\u2010mental\u2010health\u2010settings\u2010(cr237). Updated 2023. Accessed 11th August 2025."},{"key":"e_1_2_17_60_1","doi-asserted-by":"publisher","DOI":"10.22514\/jofph.2025.011"},{"key":"e_1_2_17_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14367"},{"key":"e_1_2_17_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221092435"},{"key":"e_1_2_17_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14505"},{"key":"e_1_2_17_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14952"},{"issue":"9","key":"e_1_2_17_65_1","first-page":"4","article-title":"Pregabalin (Lyrica), gabapentin (Neurontin) and risk of abuse and dependence: new scheduling requirements from 1 April 2019","volume":"12","author":"The Medicines and Healthcare products Regulatory Agency","year":"2019","journal-title":"Drug Saf"},{"key":"e_1_2_17_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397\u2010021\u201000247\u20103"},{"key":"e_1_2_17_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2017.11.006"},{"key":"e_1_2_17_68_1","doi-asserted-by":"publisher","DOI":"10.2217\/PGS.14.65"},{"key":"e_1_2_17_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000021"},{"key":"e_1_2_17_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12564"},{"key":"e_1_2_17_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.70442"},{"key":"e_1_2_17_72_1","unstructured":"ClinPGx.Annotation of RNPGx guideline for carbamazepine oxcarbazepine and HLA\u2010A HLA\u2010B.https:\/\/www.clinpgx.org\/chemical\/PA448785\/guidelineAnnotation\/PA166422201. Accessed 6th November 2025."},{"key":"e_1_2_17_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1312"},{"key":"e_1_2_17_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12325"},{"key":"e_1_2_17_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109787"},{"key":"e_1_2_17_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15818"},{"key":"e_1_2_17_77_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31826aac73"},{"key":"e_1_2_17_78_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16053"},{"key":"e_1_2_17_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2024.1037"},{"key":"e_1_2_17_80_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002484"},{"key":"e_1_2_17_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15498"},{"key":"e_1_2_17_82_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397\u2010021\u201000225\u20109"},{"key":"e_1_2_17_83_1","unstructured":"NHS Blood and Transplant.2023User guide for histocompatibility and immunogenetics diagnostics serviceshttps:\/\/hospital.blood.co.uk\/diagnostic-services\/user-guides\/"},{"key":"e_1_2_17_84_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010004"},{"key":"e_1_2_17_85_1","unstructured":"The Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines.Carbamazepine: genetic testing recommended in some Asian populations. Drug safety update.2008;1(9):2."},{"issue":"5","key":"e_1_2_17_86_1","first-page":"A1","article-title":"Carbamazepine, oxcarbazepine and eslicarbazepine: potential risk of serious skin reactions","volume":"6","author":"The Medicines and Healthcare products Regulatory Agency","year":"2012","journal-title":"Drug Saf"},{"key":"e_1_2_17_87_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100021880"},{"key":"e_1_2_17_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2008"},{"key":"e_1_2_17_89_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000156354.20227.F0"},{"key":"e_1_2_17_90_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs\u20102021\u20100126"},{"key":"e_1_2_17_91_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12058"},{"key":"e_1_2_17_92_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1190"},{"key":"e_1_2_17_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.10"},{"key":"e_1_2_17_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12217"},{"key":"e_1_2_17_95_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.162"},{"key":"e_1_2_17_96_1","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000211"},{"key":"e_1_2_17_97_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102250\u20102"},{"key":"e_1_2_17_98_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000004008"},{"key":"e_1_2_17_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2020.106321"},{"key":"e_1_2_17_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.09.011"},{"key":"e_1_2_17_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000531"},{"key":"e_1_2_17_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7859"},{"key":"e_1_2_17_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2018.06.024"},{"key":"e_1_2_17_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14240"},{"key":"e_1_2_17_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12570"},{"issue":"7","key":"e_1_2_17_106_1","first-page":"16","article-title":"Association between HLA\u2010B15:02 allele and antiepileptic drug\u2010induced severe cutaneous reactions in Hong Kong Chinese: a population\u2010based study","volume":"20","author":"Kwan PKL","year":"2014","journal-title":"Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi"},{"key":"e_1_2_17_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2014.05.025"},{"key":"e_1_2_17_108_1","doi-asserted-by":"publisher","DOI":"10.2217\/pme\u20102022\u20100126"},{"key":"e_1_2_17_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1433506"},{"key":"e_1_2_17_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/tan.15045"},{"issue":"2","key":"e_1_2_17_111_1","first-page":"26","article-title":"HLA\u2010B1502 in Iranian children with anticonvulsant drugs\u2010induced skin reactions","volume":"11","author":"Tonekaboni SH","year":"2017","journal-title":"Iran J Child Neurol"},{"key":"e_1_2_17_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13509"},{"key":"e_1_2_17_113_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2014.34.5.372"},{"key":"e_1_2_17_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2015.09.006"},{"key":"e_1_2_17_115_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2014.0667"},{"key":"e_1_2_17_116_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12053"},{"key":"e_1_2_17_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2022.12.001"},{"key":"e_1_2_17_118_1","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2015.2674"},{"key":"e_1_2_17_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2024.02.006"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70559","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70559","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70559","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:33:44Z","timestamp":1784097224000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/bcp.70559"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70559","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]}}}